Rationale: Developing an optimal medication strategy poses a challenging task in fragile patients after left atrial appendage closure (LAAC). We report an optimal nonvitamin K antagonist oral anticoagulant (NOAC) therapy in a warfarin-sensitive patient after LAAC.
Introduction
Patients with nonvalvular atrial fibrillation (NVAF) are at increased risk of thrombosis, and left atrial appendage (LAA) is considered as an approximate 90% source of thromboembolism. [1] Oral anticoagulation (OAC) is a standard therapy for preventing stroke or systemic embolism (SSE). Whereas, LAA closure (LAAC) may represent a preferable alternative in patients who are at high risk of SSE as well as clear contraindications for OAC (class IIb, level of evidence C). [2] After successful LAAC, short-term OAC is of great significance to prevent on-device thrombus formation without increasing the risk of bleeding complication. [3] At present, post-LAAC medical strategies recommended by consensus include a combination of warfarin and aspirin for at least 6 weeks, followed by 6 months dual antiplatelet therapy (DAPT) with clopidogrel and lifelong management of aspirin. [3] Nevertheless, owing to inter-and intrapatient variability, warfarin appears to be unsuitable for patients with poor time in therapeutic range and high risk of bleeding. Thus, developing the optimal medication strategy poses a challenging task in these fragile patients. Although the role of nonvitamin K antagonists (NOACs) remains undefined after LAAC, rivaroxaban was chosen as a favorite in consideration of available evidence and patient's characteristic. At 2 months follow-up, transoesophageal echocardiography (TEE) result supported our choice.
Case report
Approval for the study by the local institution review board was not required because it was a case report. The patient provided a written informed consent. A 77-year-old persistent NVAF male (weight of 50 kg) with a history of subtotal gastrectomy and moderate renal insufficiency (creatinine clearance rate of 45 mL/minute), who had been taking warfarin with the dosage of 1.25 mg daily for 3 weeks, suffered from a moderate gum bleeding at the presence of international normalized ratio (INR) being 3.41 outside the hospital. The patient's gum bleeding was well controlled after the discontinuity of warfarin. After admission, warfarin at the dosage of 1.25 mg daily was given again for the prevention of SSE. Similar to last time, the patient undergone serious gum hemorrhage with the INR of 3.05. At this juncture, warfarin was discontinued and vitamin K1 5 mg was immediately administrated via intravenous infusion. About 1 hour later, the patient's gum bleeding improved, and INR value returned to 2.07. The genetic testing for warfarin showed that the patient carries reduced-function alleles of VKORC1 (AA) and CYP2C9 ( * 1/ * 3). Thus, he was considered as a warfarin-sensitive gene carrier and less likely to do well on warfarin. Meanwhile, when regarding a high risk of stroke (CHA 2 DS 2 -VASc score of 2) and intolerance to OAC of the present patient, LAAC was regarded as a preferable option on the basis of patient's aspiration. Afterward, a 12 mm WATCHMAN device (Boston Scientific) was successful implanted into LAA without spillage around device, and radiofrequency ablation was performed at the same time (Fig. 1A, B) . Inevitably, post-LAAC OAC was necessary until complete device endothelialization. Finally, rivaroxaban at the sustained dosage of 15 mg daily was managed after comprehensive discussion with the clinical pharmacist. After bimestrial usage of rivaroxaban 15 mg daily, complete endothelialization on the surface of device was detected via TEE, and no peridevice spillage and adverse event occurred during follow-up (Fig. 1C) .
Discussion
LAAC is a nonpharmacologic alternative for SSE prevention in patients with NVAF, which is recommended by current clinical practice guidelines. [2] Originally, enthusiasm for LAAC was dampened by an unexpected high incidence of periprocedural complications. [4] In the early stage following the LAAC, clots may form on the surface of device, and thus preventive strategy should be applied until complete endothelialization on device. However, uncertainty remains on the focus of optimal postprocedural drug regimen and duration of treatment. Currently accepted drug strategy comes mainly from 2 randomized clinical trials comparing LAAC with vitamin K antagonist, namely, PROTECT AF and PREVAIL. [4] [5] [6] Of which, patients were taken a coadministration of warfarin plus aspirin 75 mg for 45 days, followed by the combination of aspirin 75 mg and clopidogrel 75 mg for 6 months, and lifelong management of aspirin 75 mg. Based on the above-mentioned strategy, 3.4% of patients occurred a device-surface thrombus during TEE evaluation at 45 days post-LAAC. [5, 6] It is of note that warfarin dose have significant ethnic difference due to alleles of VKORC1 and CYP2C9. [7] VKORC1
(rs9923231) was a common single-nucleotide polymorphism (SNP) in VKORC1, leading to a protein product with no enzyme activity. [8] The mutation frequency of VKORC1 (rs9923231) is about 40% in Caucasians and 10% in Africans, but affects up to near 95% in Asians. [8] Unlike VKORC1 (rs9923231), the mutation rate of CYP2C9 * 3 was only 2% to 5% in Asians. [9] In the present case, the reduced-function allele carrier of both VKORC1 and CYP2C9 induced a relatively low dosage of warfarin. In addition, elderly person and low weight (50 kg) were also factors that leaded to low warfarin dose. [10] Therefore, the predicted dose of warfarin was 1.3 mg/daily by using a web application (www.warfarindosing.org) that involved clinical variables and also SNPs in VKORC1 and CYP2C9, which was line with the actual warfarin dosage in the present patient. [10] It is also noteworthy that the patient experienced continuous gum bleeding at the presence of INR around 3. Collectively, he was considered as a warfarin-sensitive patient, and hard to reach satisfying INR control.
Other optimal antithrombotic therapy should be considered in such fragile patients. In the PLAATO study, patients were treated with DAPT consisting of aspirin and clopidogrel for 4 to 6 weeks after LAAC, and no device-surface thrombus occurred during TEE follow-up. [11] Thus, short-term drug regimen with DAPT appears to be a reasonable option in patients intolerant to warfarin. Whereas, in a recent EWOLUTION study, those prescribed DAPT after WATCHMAN implantation showed a numerically highest rate of device-associated thrombus when compared to warfarin (3.1% vs 0.8%). [12] Interestingly, patients on NOACs had the numerically lowest rate of thrombus information on device as well as major bleeding in comparison to DAPT (1.3% vs 3.1% for device-associated thrombus; 1.9% vs 2.4% for major bleeding). [12] On the basis of above-mentioned data, NOACs are likely to come with a good balance between device-related thrombus and bleeding in high risk patients. Several reasons needed to be considered with regard to an optimal choice of NOACs: only dabigatran and rivaroxaban are available in China; the patient had a history of subtotal gastrectomy, and the use of dabigatran may increase the risk of gastrointestinal bleeding [13] ; rivaroxaban depend on lesser degree on renal excretion compared to dabigatran (36% vs 80%), and the patient had a moderate renal insufficiency with Ccr of 45 mL/minute [14] ; and reduced dosage of rivaroxaban 15 mg daily is recommended based on the results of ROCKET-AF and J-ROCKET AF. [15, 16] Summarily, rivaroxaban 15 mg daily represents a preferable choice. The patient had been doing well without device-related thrombus and bleeding at 2 months follow-up.
Based on the clinical setting of this case and current evidence, NOACs may represent a reasonable alternative regarding the Medicine inhibition of device-associated thrombus and bleeding in patients intolerant to warfarin. In addition, further studies on evaluation of the optimal drug strategy in LAAC patients are necessary.
Conclusion
A post-LAAC treatment with NOACs may be a viable regimen in patients intolerant to warfarin. Whereas, further design of randomized clinical trials as well as real-world studies on evaluation of NOACs in LAAC patients are necessary.
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